Chordate Medical introduces new trademark for Migraine Treatment: Ozilia® – Your Migraine Relief

During the International Headache Congress in Seoul from September 14 to 17, Chordate Medical is introducing the new brand Ozilia® Migraine for the company’s migraine treatment. Ozilia® Migraine replaces K.O.S as the brand name in all markets where Chordate is active.

“This is the next step in the rollout and commercialization of the treatment in our focus markets. Migraine is predominantly a women’s health matter, and the previous designation, K.O.S, has long felt as too technical and rather uninspiring as a brand. The meaning of the name Ozilia® revolves around her need for freedom – and that is also the core of what we want to offer to all people in the world who suffer from migraines”, says Anders Weilandt, CEO of Chordate.

Ozilia® Migraine will be showcased for the first time at the IHC in Seoul, the largest international platform for headache experts and migraine specialists.

“The interest in our study and its results is significant within the migraine field. Exhibiting at this congress is an excellent opportunity for us to introduce Ozilia® Migraine as a drug-free treatment option with a very favorable side effect profile and long-lasting preventive effects.”

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy